Results 41 to 50 of about 19,613 (205)

Perinatal death in pig models of hypertrophic cardiomyopathy carrying sarcomere pathogenic variants

Journal of Molecular and Cellular Cardiology Plus
Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant disease caused by genetic variants in sarcomeric proteins, particularly in myosin binding protein C3 (MYBPC3) and myosin heavy chain 7 (MYH7).
Tatiana Flisikowska, Björn Petersen, Giulia Mearini, Daniela Huber, Mayuko Kurome, Melanie Stoff, Saskia Schlossarek, Andrea Lucas-Hahn, Eckhard Wolf, Judith Montag, Angelika Schnieke, Lucie Carrier   +11 more
doaj   +1 more source

Pharmacological therapy of acute heart failure: what is available now and what is expected in future

Вестник анестезиологии и реаниматологии, 2020
The objective: to present an overview of current approaches to pharmacological therapy of acute heart failure (AHF).Results: the discussion focuses on drugs that are currently available and being actively studied in ongoing clinical trials. Disadvantages
A. A. Eremenko
doaj   +1 more source

Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging

Journal of Cardiovascular Development and Disease, 2022
Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart disease with an estimated prevalence of 0.2–0.5%. Although the prognosis of HCM is relatively good, with an annual general mortality of ~0.7%, some patients have an increased risk of ...
Takeshi Kitai, Andrew Xanthopoulos, Shoko Nakagawa, Natsuko Ishii, Masashi Amano, Filippos Triposkiadis, Chisato Izumi   +6 more
doaj   +1 more source

The E3 Ligase RNF115 Aggravates Pathological Cardiac Hypertrophy via Ubiquitin‐Mediated Degradation of SPTBN1

Advanced Science, EarlyView.
In response to hypertrophic stimuli, increased c‑JUN phosphorylation upregulates RNF115, leading to SPTBN1 ubiquitination and degradation. which promotes F‑actin depolymerization and YAP activation, driving cardiac hypertrophy. The RNF115 inhibitor DTD effectively suppresses SPTBN1 ubiquitination and cardiac hypertrophy.
Yan Zu, Shiqing Chen, Ji Chen, Liuliu Ruan, Bowen Li, Weijian Chu, Shichen Huang, Dian Yu, Jing Tian, Yuhan Zhao, Yi Han, Xin Tang, Yong Ji   +12 more
wiley   +1 more source

Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice

Journal of Molecular and Cellular Cardiology Plus
Type 2 diabetes mellitus (T2DM) is a metabolic disease and comorbidity associated with several conditions, including cardiac dysfunction leading to heart failure with preserved ejection fraction (HFpEF), in turn resulting in T2DM-induced cardiomyopathy ...
Darshini A. Desai, Akhil Baby, Kalyani Ananthamohan, Lisa C. Green, Mohammed Arif, Brittany C. Duncan, Mohit Kumar, Rohit R. Singh, Sheryl E. Koch, Sankar Natesan, Jack Rubinstein, Anil G. Jegga, Sakthivel Sadayappan   +12 more
doaj   +1 more source

Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy

Hellenic Journal of Cardiology, 2023
Hypertrophic cardiomyopathy (HCM) is the most common genetically inherited cardiomyopathy with an autosomal dominant inheritance pattern. A disease-causing gene is found between 34% and >60% of the times and the two most frequently mutated genes, which ...
Ilias K. Gartzonikas, Katerina K. Naka, Aris Anastasakis   +2 more
doaj   +1 more source

Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives

Cureus
Mavacamten is a first-in-class, selective allosteric inhibitor of cardiac myosin adenosine triphosphatase (ATPase) that has emerged as a novel therapeutic option for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) who remain refractory to conventional therapy, such as beta-blockers and calcium channel blockers.
Ramadan, Mahmoud M, Al-Najjar, Raghad A, Abady, Rokia S, Obaid, Hala A, Mostafa, Yasmeen A, Al-Obeid, Mohammad T, Elmahal, Mohammed   +6 more
openaire   +2 more sources

Human Fibroblast–Myeloid Cell Tissue Atlas Across the Lungs, Synovium, Skin, and Heart

Arthritis &Rheumatology, EarlyView.
Objective The availability of single‐cell RNA sequencing (scRNAseq) data in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald, Katerina Apostolopoulou, Olympia Hardy, Melpomeni Toitou, Gabriela Kania, Przemyslaw Blyszczuk, Raphael Micheroli, Thomas D. Otto, Mariola Kurowska‐Stolarska, Caroline Ospelt   +9 more
wiley   +1 more source

Novel drugs targeting genetic variants: current applications and future prospects in heart failure treatment

Frontiers in Molecular Biosciences
Chronic heart failure (HF) is a common and frequently occurring disease worldwide, and its traditional treatment methods are undergoing earth-shaking changes.
Xiang Li, Suwen Bai, Yumei Luo
doaj   +1 more source

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

Cytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook, Edna C. Hardeman, Peter W. Gunning   +2 more
wiley   +1 more source